<DOC>
	<DOCNO>NCT00076284</DOCNO>
	<brief_summary>This study determine four dos GW873140 safely give adult low amount virus ( HIV-1 ) body . GW873140 new type anti-HIV drug call CCR5 receptor antagonist . CCR5 receptor T cell ( type white blood cell ) HIV-1 enters infects cell . GW873140 intend block CCR5 receptor HIV-1 enter cell . HIV-1-infected patient 18 year age old may eligible study . Candidates screen medical history physical examination , electrocardiogram , blood urine test . Some blood drawn use test patient 's HIV-1 type see study drug might lower amount HIV-1 blood . Women become pregnant pregnancy test . Participants hospitalize 12 day . They randomly assign take one follow four treatment 10 day : 1 ) 200 mg GW873140 day , placebo ( look-alike pill active ingredient ) ; 2 ) 200 mg GW873140 twice day , placebo ; 3 ) 400 mg GW873140 day , placebo ; 600 mg GW873140 twice day , placebo . Participants record meal eat diary card . In addition , undergo follow test procedure : During treatment - Assessment HIV classification ( day 1 ) - Review meal diary card ( day 1,2,3,4,5,8 , 10 ) - Review HIV-associated condition , medication take besides study drug , well-being ( day 1,2,3,4,5,8,10 , 11 ) - Check vital sign , include blood pressure , pulse , temperature ( day 1,2,3,4,5,6,7,8,10 , 11 ) - Weight assessment ( day 1 10 ) - Electrocardiogram measure electrical activity heart ( day 1,2,3,8 , 10 ) - Blood draw routine laboratory test , measure T-cell count , measure HIV level ( day 1,2,5,10 , 11 ) - Urine test ( day 1 10 ) Post-treatment - Blood test monitor effect GW873140 lower HIV count ( day 12 , 15 , 17 , 19 ) Follow-up visit ( 2 week last drug dose -- day 24 ) - Review medication take general well-being - Check vital sign - Physical examination - Blood urine test .</brief_summary>
	<brief_title>GW873140 Treat HIV-1 Infected Adults</brief_title>
	<detailed_description>The development resistance currently market drug HIV infection observe major reason failure therapy . In particular , great need drug new target novel mechanism action new target . Most currently approve drug target toward inhibition viral enzyme . However , process viral entry fusion become active area research . Among step involve viral entry , bind HIV CD4 co-receptors cell surface important promise target new drug development . GW873140 CCR5 antagonist Phase I clinical development viral entry inhibitor treatment HIV infection . GW873140 demonstrate vitro antiviral activity IC50 CCR5-tropic HIV-1 1nM equal 0.5ng/mL ) , shift 8-10 fold ( 10nM equal 0.5ng/mL ) presence physiological concentration human plasma protein . A study investigate safety , tolerability , pharmacokinetics escalate single ( 50-1200mg ) repeat ( 200-800mg BID ) dose GW873140 conduct 70 healthy volunteer ( GW873140/001 ) . Preliminary result indicate GW873140 well-tolerated dose 1200 mg follow single dose 800 mg BID follow multiple-dose . Additionally , food show increase AUC Cmax 400 mg single dose 1.7-and 2.2-fold , respectively . Concentrations protein bind correct IC90 achieve follow oral dose vivo bind study healthy subject demonstrate great 97 % receptor occupancy 2 12 hour multiple dos 68-88 % receptor occupancy 24 hour single dose , despite plasma concentration near detectable limit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>INCLUSION CRITERIA : A subject eligible inclusion study follow criterion apply : 1 . Healthy adult male age great equal 18 OR Healthy adult female age great equal 18 , nonchildbearing potential , define : Women surgically sterile postmenopausal , indicate history menses minimum one year date screen visit . Healthy adult female age great equal 18 childbearing potential , agree use double barrier method ( e.g . condom+diaphragm ) start screen visit follow visit ( Day 24 ) . Note : Spermicides and/or hormonal contraceptive consider sufficient form contraception study . 2 . Screening plasma HIV1 RNA great equal 5,000 less equal 250,000 copies/mL . 3 . Viral load within past 3090 day screen visit must within 0.5log screen HIV1 RNA . 4 . Not take antiretroviral therapy precede 3 month screen visit . 5 . CD4 cell count great equal 200 cells/mm ( 3 ) historical nadir great equal 200 cells/mm ( 3 ) . 6 . CCR5tropic virus base viral tropism assessment screen visit . 7 . Normal rest 12lead electrocardiogram screen visit . 8 . Signed date write informed consent prior admission study . 9 . In addition inclusion criterion list , patient must meet follow inclusion criterion : Willingness ability fast 10 hour except water 9:00 p.m. 7:00 a.m. eight study day . Willingness ability eat 30 % fat diet 10 day treatment period study . Willingness allow store blood sample use future test study HIV disease immune function . EXCLUSION CRITERIA : A subject eligible inclusion study follow criterion apply : 1 . CXCR4 tropic virus base viral tropsin assessment screen visit . 2 . Chronic diarrhea ( great 3 stools/day ) 3 . Subject history oropharyngeal candidiasis C AIDSdefining illness accord 1993 Centers Disease Control ( CDC ) AIDS surveillance definition . 4 . Greater two prior ARV regimen . 5 . Any acute laboratory abnormality screen , opinion investigator , preclude subject 's participation study investigational compound . Any grade 4 laboratory abnormality screen exclude subject study participation unless investigator provide compel explanation laboratory result ( ) assent sponsor . 6 . Significant blood loss ( 1 pint whole blood ) within 56 day screen visit study . 7 . Previous participation experimental drug trial ( ) within 30 day screen visit study . 8 . Any conduction delay , regardless clinical significance screen ECG . 9 . History clinically relevant pancreatitis hepatitis within previous 6 month . 10 . Any condition , opinion investigator , may interfere subject 's ability comply dose schedule protocol evaluation ( include alcohol drug abuse ) might compromise safety subject . 11 . Any condition , opinion investigator , might interfere absorption , distribution , metabolism excretion drug diabetes mellitus , hyperthyroidism , malabsorption syndrome , etc . 12 . History cholecystectomy , cholelithiasis cholecystitis . 13 . Any immunization within 30 day prior first dose investigational product . 14 . History drug allergy opinion investigator , contraindicate subject 's participation study know hypersensitivity study medication . 15 . Treatment radiation therapy cytotoxic chemotherapeutic agent within 30 day investigational product administration anticipate need treatment within study . 16 . Treatment immunomodulating agent ( interleukin , interferon ) agent know antiHIV activity ( hydroxyurea , foscarnet , NRTIs ) within 30 day investigational product administration . 17 . Use steroid ( oral ) within 30 day first dose investigational product . 18 . Prior treatment entry , attachment fusion inhibitor , experimental approve . 19 . Pregnant woman woman breastfeed . 20 . Subjects refrain drink grapefruit juice eat grapefruit within 3 day prior first dose study medication collection final pharmacokinetic blood sample . 21 . Use prescription nonprescription medication GSK APPROVED MEDICATION LIST GW873140 . Medications approve list , need discontinue 7 day prior first dose investigational product ( drug nonhepatic inducer ) 30 day prior first dose investigational product ( drug hepatic inducer ) 5 day post dose . To clarify exclusion patient hepatitis pancreatitis , follow patient exclude : Patients diagnosis acute viral hepatitis infection precede six month Patients history AST ALT elevation five time normal great precede six month Patients diagnose pancreatitis precede six month elevation lipase two time normal great symptom suggestive pancreatitis ( i.e . nausea , vomit , epigastric pain ) . Patients evidence chronic hepatitis B C exclude study participation clinically asymptomatic , liver enzymes less five time normal , evidence hepatic synthetic dysfunction ( i.e . PT less 1.5 time upper limit normal ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>CCR5 Antagonist</keyword>
	<keyword>Coreceptor Inhibitor</keyword>
	<keyword>Fusion Inhibitor</keyword>
	<keyword>Entry Inhibitor</keyword>
	<keyword>Antiretroviral</keyword>
	<keyword>HIV</keyword>
</DOC>